Gujarat Themis BiosynBOM:506879 +3.27%72 Net Margin % is 24.62% as of Mar. 2026, which is 19% below its 10-year median of 30.25. GuruFocus rates BOM:506879 with a GF Score™ of 72/100 and a GF Value™ of ₹312.95 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 954 Drug Manufacturers companies, Gujarat Themis Biosyn ranks better than 93.5% on this metric.
The historical rank and industry rank for Gujarat Themis Biosyn's Net Margin % or its related term are showing as below:
BOM:506879'
s Net Margin % Range Over the Past 10 Years
Min: 9.97 Med: 30.25 Max: 39.13
Current: 28.15
BOM:506879's Net Margin % is ranked better than 93.5% of 954
companies
in the Drug Manufacturers industry
Industry Median: 5.695
vs BOM:506879: 28.15
Gujarat Themis Biosyn (BOM:506879) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Gujarat Themis Biosyn Net Margin % Related Terms
Gujarat Themis Biosyn Net Margin % Historical Data
* Premium members only.
The historical data trend for Gujarat Themis Biosyn's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Themis Biosyn's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Themis Biosyn Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gujarat Themis Biosyn's Net Margin % distribution charts can be found below:
* The bar in red indicates where Gujarat Themis Biosyn's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Themis Biosyn (BOM:506879) has a Net Margin % of 24.62% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Gujarat Themis Biosyn and its competitors. This is 19% below median its historical median of 30.25. Over the past decade, Gujarat Themis Biosyn's Net Margin % has ranged from 9.97 to 39.13. According to the industry distribution chart, Gujarat Themis Biosyn ranks #62 out of 954 companies in the Drug Manufacturers industry, placing it in the top 6.5%.
Is Gujarat Themis Biosyn's Net Margin % too high?
Gujarat Themis Biosyn's current Net Margin % of 24.62% is 19% below median its 10-year median of 30.25. Over the past 10 years, this metric has ranged from a low of 9.97 to a high of 39.13. The Drug Manufacturers industry median Net Margin % is 5.70. Gujarat Themis Biosyn's value of 24.62% is 332.3% above this industry median. Based on the distribution chart, Gujarat Themis Biosyn ranks #62 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gujarat Themis Biosyn has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Themis Biosyn's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gujarat Themis Biosyn ranks #62 out of 954 companies for Net Margin %. This places Gujarat Themis Biosyn in the top 7% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.70. Gujarat Themis Biosyn's value of 24.62% is 332.3% above this benchmark. Historically, Gujarat Themis Biosyn's own Net Margin % has ranged from 9.97 to 39.13 over the past decade. While the company's 10-year median is 30.25 vs. the industry median of 5.70, Gujarat Themis Biosyn has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.70, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Themis Biosyn's current Net Margin % of 24.62% is 332.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Gujarat Themis Biosyn and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Themis Biosyn's current Net Margin % is 24.62%, which is 19% below median its own 10-year median of 30.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Themis Biosyn stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Themis Biosyn (BOM:506879) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹312.95, compared to a current price of ₹396.80 — trading 26.8% above its estimated fair value. The current Net Margin % is 24.62%, which is 19% below median its 10-year median of 30.25 and 332.3% above the Drug Manufacturers industry median of 5.70. Gujarat Themis Biosyn's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Gujarat Themis Biosyn (BOM:506879), the current Net Margin % is 24.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gujarat Themis Biosyn (BOM:506879) Overvalued in 2026?
Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued.
The current stock price of ₹396.80 is trading 26.8% above its estimated GF Value™ of ₹312.95.
GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.
Key valuation signals for BOM:506879:
Net Margin %: 24.62% (19% below median its 10-year median of 30.25)
GF Value™: ₹312.95 vs. price of ₹396.80 (26.8% above fair value)
Industry Position: 332.3% above the Drug Manufacturers median (#62 of 954)
No single metric tells the full story. See the BOM:506879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
72GF Score
Get the complete analysis for BOM:506879
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506879 has been successfully added to your 
